Nafarelin Disease Interactions

The use of nafarelin nasal is contraindicated in patients with undiagnosed, abnormal vaginal bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present.

Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists. These have included patients with a history of seizures, epilepsy, cerebrovascular disorder, central nervous anomalies such as tumors, and patients receiving concomitant medications that have been associated with convulsions. Convulsions have also been reported in patients with none of these conditions. Caution is advised when administering nafarelin to patients with any of these conditions.

Nafarelin induces a hypoestrogenic effect that results in a small loss in bone density. Therapy with nafarelin should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).

Nafarelin therapy induces a release of pituitary gonadotropins (LH and FSH). Ovarian cysts or enlargement of existing ovarian cysts (primarily in women with polycystic ovarian disease) have been reported during the first months of treatment. Spontaneous resolution generally occurs in 4 to 6 weeks of therapy, but some cases require discontinuation of nafarelin therapy.